GLSI

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for breast cancer and other cancers. The company's lead product candidate, GP2, is an immunotherapy designed to prevent breast cancer recurrences in patients with HER2/neu-positive tumors who have previously undergone surgery. Greenwich LifeSciences is conducting Phase III clinical trials of GP2 as a potential treatment to reduce recurrence rates in HER2 3+ breast cancer patients. The company's therapeutic approach aims to stimulate the immune system to recognize and eliminate cancer cells expressing the HER2/neu protein. Greenwich LifeSciences acquired the rights to GP2 and related technologies from the University of Texas MD Anderson Cancer Center. The company represents a focused development strategy targeting a specific breast cancer patient population with an unmet medical need.